25.30
전일 마감가:
$25.45
열려 있는:
$25.55
하루 거래량:
1.70M
Relative Volume:
1.07
시가총액:
$1.71B
수익:
$2.76B
순이익/손실:
$-358.70M
주가수익비율:
-5.0905
EPS:
-4.97
순현금흐름:
$-35.90M
1주 성능:
-12.34%
1개월 성능:
-9.74%
6개월 성능:
-42.13%
1년 성능:
-27.07%
Quidelortho Corporation Stock (QDEL) Company Profile
명칭
Quidelortho Corporation
전화
(858) 552-1100
주소
9975 SUMMERS RIDGE ROAD, SAN DIEGO, CA
QDEL을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
QDEL
Quidelortho Corporation
|
25.30 | 1.95B | 2.76B | -358.70M | -35.90M | -4.97 |
![]()
ABT
Abbott Laboratories
|
124.42 | 229.71B | 43.11B | 13.98B | 6.66B | 7.98 |
![]()
BSX
Boston Scientific Corp
|
103.78 | 154.35B | 17.55B | 2.03B | 2.72B | 1.37 |
![]()
SYK
Stryker Corp
|
387.32 | 149.60B | 23.22B | 2.86B | 3.58B | 7.40 |
![]()
MDT
Medtronic Plc
|
89.70 | 114.97B | 33.54B | 4.66B | 5.19B | 3.62 |
![]()
EW
Edwards Lifesciences Corp
|
76.56 | 45.92B | 5.54B | 4.18B | 623.10M | 7.00 |
Quidelortho Corporation Stock (QDEL) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-05-08 | 업그레이드 | Jefferies | Hold → Buy |
2024-12-11 | 업그레이드 | Citigroup | Neutral → Buy |
2024-12-10 | 개시 | Jefferies | Hold |
2024-09-19 | 재개 | UBS | Neutral |
2024-09-05 | 업그레이드 | Craig Hallum | Hold → Buy |
2024-03-04 | 다운그레이드 | UBS | Neutral → Sell |
2024-02-14 | 다운그레이드 | JP Morgan | Neutral → Underweight |
2023-12-11 | 다운그레이드 | Citigroup | Buy → Neutral |
2022-12-12 | 업그레이드 | Citigroup | Neutral → Buy |
2022-12-07 | 개시 | RBC Capital Mkts | Outperform |
2022-10-14 | 업그레이드 | UBS | Sell → Neutral |
2022-09-19 | 개시 | Citigroup | Neutral |
2022-07-20 | 개시 | UBS | Sell |
2022-06-17 | 재개 | JP Morgan | Neutral |
2022-02-22 | 업그레이드 | Raymond James | Outperform → Strong Buy |
2021-01-22 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
2020-05-12 | 다운그레이드 | JP Morgan | Neutral → Underweight |
2020-03-26 | 다운그레이드 | Barclays | Overweight → Equal Weight |
2018-10-23 | 재개 | Raymond James | Strong Buy |
2018-03-08 | 업그레이드 | Raymond James | Outperform → Strong Buy |
2018-01-22 | 재확인 | Barclays | Overweight |
2018-01-04 | 업그레이드 | CL King | Neutral → Buy |
2017-09-19 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
2017-07-18 | 업그레이드 | Canaccord Genuity | Hold → Buy |
2017-07-18 | 업그레이드 | William Blair | Mkt Perform → Outperform |
2017-04-25 | 재확인 | Canaccord Genuity | Hold |
2017-02-17 | 개시 | CL King | Neutral |
2016-12-16 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
2016-06-13 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
2016-02-18 | 재확인 | Barclays | Overweight |
2016-02-09 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
2016-01-08 | 재확인 | Canaccord Genuity | Buy |
2015-12-14 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
2015-09-02 | 개시 | Barclays | Overweight |
2013-07-31 | 재확인 | Canaccord Genuity | Buy |
2011-03-03 | 다운그레이드 | Wedbush | Outperform → Neutral |
모두보기
Quidelortho Corporation 주식(QDEL)의 최신 뉴스
QuidelOrtho Corporation Stock Analysis and ForecastBreakthrough stock performance - jammulinksnews.com
Is QuidelOrtho Corporation a good long term investmentFree Stock Index Interpretation - Autocar Professional
What analysts say about QuidelOrtho Corporation stockDynamic investment opportunities - Autocar Professional
RBC Capital Maintains a Buy Rating on QuidelOrtho Corporation (QDEL), Sets a $60 PT - MSN
What drives QuidelOrtho Corporation stock priceExceptional stock performance - jammulinksnews.com
QuidelOrtho, Acadia Healthcare, Elevance Health, Molina Healthcare, and Alignment Healthcare Stocks Trade Down, What You Need To Know - MSN
Real Labs, Actual Decisions With Actionable Six Sigma Metrics - The Malaysian Reserve
QuidelOrtho Announces Featured ADLM Session on Six Sigma Insights for Lab Performance - AInvest
QuidelOrtho to present at ADLM on Six Sigma lab performance improvement. - AInvest
Six Sigma Lab Excellence: Top Medical Experts Share Game-Changing Performance Metrics at ADLM Conference - Stock Titan
10 Undervalued Medical Device Stocks to Buy Now - Insider Monkey
Investors in QuidelOrtho (NASDAQ:QDEL) from five years ago are still down 88%, even after 3.8% gain this past week - simplywall.st
QuidelOrtho Corporation and Buildman Laboratories AG Announces Availability of the BuHLMANN FCAL Turbidimetric Immunoassays on Vitroal Pancreatic Elastase - MarketScreener
QuidelOrtho and Bühmann Laboratories AG announce availability of Fecal Calprotectin (Fcal®) Turbo and Fecal Pancreatic Elastase (Fpela®) Turbo assays on Vitros systems as a Microtip partnership assay (Mpa) - MarketScreener
QuidelOrtho's New 10-Minute Diagnostic Tests Transform IBD and Pancreatic Disease Detection - Stock Titan
Acadia Healthcare, 10x Genomics, Amphastar Pharmaceuticals, Myriad Genetics, and QuidelOrtho Stocks Trade Down, What You Need To Know - MSN
A Look Back at Medical Devices & SuppliesImaging, Diagnostics Stocks’ Q1 Earnings: QuidelOrtho (NASDAQ:QDEL) Vs The Rest Of The Pack | FinancialContent - FinancialContent
Nephron Initiates QuidelOrtho(QDEL.US) With Hold Rating, Announces Target Price $40 - 富途牛牛
Best Value Stocks to Buy for July 8th - The Globe and Mail
QuidelOrtho announces key leadership changes - Medical Buyer
QuidelOrtho Strengthens Leadership Team With Appointments of Senior Vice Presidents for Global Quality and Clinical & Regulatory Affairs | QDEL Stock News - GuruFocus
Press Release: QuidelOrtho Strengthens Leadership Team With Appointments of Senior Vice Presidents for Global Quality and Clinical & Regulatory Affairs - 富途牛牛
5 Revealing Analyst Questions From QuidelOrtho’s Q1 Earnings Call - Yahoo Finance
Here's Why QuidelOrtho (QDEL) is a Strong Growth Stock - Nasdaq
RBC Capital Keeps Their Buy Rating on QuidelOrtho (QDEL) - The Globe and Mail
QuidelOrtho's Russell 1000 Exit: Opportunity in the Shadows of Index Exclusion - AInvest
QuidelOrtho Corporation(NasdaqGS: QDEL) added to Russell 3000 Growth Index - MarketScreener
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now - Yahoo Finance
QuidelOrtho Nabs LEX in $100M M&A - San Diego Business Journal
What Makes QuidelOrtho (QDEL) a New Buy Stock - Nasdaq
Why QuidelOrtho (QDEL) is a Top Growth Stock for the Long-Term - Yahoo Finance
Should Value Investors Buy QuidelOrtho (QDEL) Stock? - Yahoo Finance
This QuidelOrtho Insider Increased Their Holding In The Last Year - simplywall.st
QuidelOrtho Declares that its Molecular Diagnostics Approach will be Refocused - MSN
Lex seeks FDA clearance ahead of $100M Quidelortho takeover - BioWorld MedTech
QuidelOrtho set to buy LEX Diagnostics for $100m after FDA approval trigger - Cambridge Independent
QuidelOrtho Corp (QDEL) Trading 4% Higher on Jun 9 - GuruFocus
QuidelOrtho seeks FDA approval to complete acquisition of LEX Diagnostics - Mugglehead Magazine
QuidelOrtho (QDEL) Down 18% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Clinical Laboratory Molecular Diagnostics for Infectious Disease Market Research 2025-2029: Biotechnology and Genomics Drive Advancements, Impact of Multiplex Assays in Diagnosis and Treatment - GlobeNewswire Inc.
Quidel at Jefferies Conference: Strategic Shift and Growth Plans - Investing.com
Transcript : QuidelOrtho Corporation Presents at Jefferies Global Healthcare Conference 2025, Jun-05-2025 08 - MarketScreener
Transcript : QuidelOrtho Corporation Presents at 45th Annual William Blair Growth Stock Conference, Jun-04-2025 08 - marketscreener.com
QuidelOrtho Corp (QDEL) Stock Price Down 2.92% on Jun 2 - GuruFocus
QuidelOrtho to discontinue Savanna platform development - MSN
QuidelOrtho (QDEL) to Acquire LEX Diagnostics Amid Strategic Shi - GuruFocus
Citi maintains Buy rating on Quidel stock amid strategic pivot - Investing.com
Quidelortho Corporation (QDEL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):